TABLE II. Summary of Mutant Frequency in the Lungs of *gpt* delta Mice Following Treatment With DEP and DEP Extract

Treatment	Amount (mg)	ID of animals	Number of colonies		Mutant frequency (10^{-5})	Average mutant frequency ± SD (10^{-5})
			Mutant	Total		
Control	0	1	7	1,016,000	0.69	0.66 ± 0.08
		2	6	836,800	0.72	
		3	3	524,200	0.57	
		Total	16	2,377,000		
DEP	0.125	1	9	780,800	1.15	1.16 ± 0.01**
		2	20	1,731,200	1.16	
		3	10	859,200	1.16	
		Total	39	3,371,200		
	0.25	1	18	1,300,800	1.38	1.40 ± 0.05***
		2	18	1,323,200	1.36	
		3	14	963,200	1.45	
		Total	50	3,587,200		
	0.5	1	10	548,800	1.82	1.97 ± 0.18***
		2	19	990,400	1.92	
		3	19	872,000	2.18	
		Total	48	2,411,200		
DEP extract	0.05	1	9	862,400	1.04	0.97 ± 0.10
		2	11	1,289,600	0.85	
		3	15	1,480,000	1.01	
		Total	35	3,632,000		
	0.1	1	12	905,600	1.33	1.28 ± 0.11**
		2	10	737,600	1.36	
		3	15	1,304,000	1.15	
		Total	37	2,947,200		
	0.2	1	11	686,400	1.60	1.78 ± 0.19***
		2	16	912,000	1.75	
		3	13	656,000	1.98	
		Total	40	2,254,400		

Statistical significance was determined using ANOVA and post hoc Tukey tests.
Significant differences between the control and DEP-treated groups are indicated (**$P < 0.01$; ***$P < 0.001$).

mutation in the lung was significantly higher at 24 weeks than at 4 weeks (Table I); however, although A:T → G:C transitions changed from 0 to 16% and 1 base deletions decreased from 29 to 8%, there was no significant difference in the mutation spectrum between the control mice at 4 and 24 weeks ($P = 0.29$, Adams–Skopek test), as demonstrated previously in several tissues of aged Big Blue® mice [Hill et al., 2005].

The spectrum of *gpt* mutations induced by DE inhalation (Table IV) indicated a prevalence of G:C → A:T transitions, with seven mutation hotspots (mutation loci identified from three or more mice at nucleotide numbers 64, 110, 115, 185, 401, 402, and 418). At nucleotide 406, both G:C → A:T transitions and G:C → T:A transversions were identified in two mice, but this nucleotide was also a mutation hotspot for G:C → T:A transversions in control mice. The predominant frameshift mutations were single-base pair deletions at G:C base pairs (9/12 = 75%).

Characteristics of the *gpt* Mutation Spectrum Induced by DEP and DEP Extract

To determine the mutation spectrum induced by DEP and DEP extract, we isolated and sequenced 127, 101, and 16 *gpt* mutants from the lungs of DEP-, DEP extract-treated, and control mice, respectively. Although G:C → A:T transitions represented the majority of the base substitutions for both DEP- and DEP extract-treated groups, G:C → T:A transversions were also common (Table V). In the mutants isolated from mice treated with DEP, 39% (50/127 mutants) of mutations were G:C → A:T transitions and 28% (35/127) were G:C → T:A transversions, whereas with DEP extract, 37% of mutations (37/101 mutants) were G:C → A:T transitions and 23% (23/101) were G:C → T:A transversions. In the instillation control mice, the majority of mutations were G:C → A:T transitions (44%, 7/16) and G:C → T:A transversions (25%, 4/16). After treatment with 0.5 mg DEP, the percentage of G:C → T:A transversions increased (from 25 to 39%), while the percentage of G:C → A:T transitions decreased (from 44 to 29%) compared to the control. It has previously been suggested that accumulation of 8-hydroxyguanine may cause an increase in G:C → T:A transversions [Arai et al., 2003]. As formation of 8-hydroxyguanine occurred in the lungs of mice after DEP treatment [Ichinose et al., 1997], the increase in the percentage of G:C → T:A transversions may be explained by DEP-catalyzed formation of 8-hydroxyguanine.

TABLE III. Classification of *gpt* Mutations Isolated From the Lungs of Control and DE-Inhalation Mice

Type of mutation in *gpt*	Control		DE		Control (weeks)						DE (weeks)					
	All		All		4		12		24		4		12		24	
	Number	%	Number	%	Number	%	Number	%	Number	%	Number	%	Number	%	Number	%
Base substitution																
Transition																
G:C → A:T (CpG site)	22 (13)	40	69 (28)	55	9 (5)	43	2 (1)	22	11 (7)	44	31 (13)	49	18 (7)	49	20 (8)	77
A:T → G:C	4	7	3	2	0	0	0	0	4	16	2	3	1	3	0	0
Transversion																
G:C → T:A	17	31	21	17	5	24	5	56	7	28	14	22	5	14	2	8
G:C → C:G	1	2	7	6	0	0	1	11	0	0	1	2	5	14	1	4
A:T → T:A	2	4	6	5	1	5	0	0	1	4	4	6	1	3	1	4
A:T → C:G	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Deletion																
−1	9	16	12	10	6	29	1	11	2	8	5	8	5	14	2	8
>2	0	0	5	4	0	0	0	0	0	0	5	8	0	0	0	0
Insertion	0	0	2	2	0	0	0	0	0	0	1	2	1	3	0	0
Other	0	0	1	1	0	0	0	0	0	0	0	0	1	3	0	0
Total	*55*	*100*	*126*	*100*	*21*	*100*	*9*	*100*	*25*	*100*	*63*	*100*	*37*	*100*	*26*	*100*

A comparison of the spectrum of mutations induced by instillation of DEP and the DEP extract (Table IV) indicates that five G:C → A:T mutation hotspots (nucleotide numbers 64, 110, 115, 401, and 418) were induced by DEP instillation. The same five G:C → A:T mutation hotspots were also induced by DE inhalation, and three mutation loci (nucleotide nos. 64, 110, and 115) were commonly induced by DEP and the DEP extract. Masumura et al. [2000] reported that *gpt* nucleotide numbers 64, 110, and 115 are mutation hotspots in nontreated mice and it is possible that components in the DE extract enhance spontaneous mutation. Therefore, mutations of nucleotide nos. 401 and 418 seem to be characteristic of DE inhalation and DEP instillation.

DISCUSSION

Following inhalation of 3 mg m^{-3} DE as SPM, the MF in the lungs of *gpt* delta transgenic mice increased with the duration of treatment, but reached a plateau by 24 weeks. Additionally, the MF of control mice was elevated at 24 weeks. The MFs in mice that inhaled DE for 4, 12, and 24 weeks were 1.7-, 3.2-, and 2.6-fold higher than the control groups, respectively (Table I). We have demonstrated that inhalation of DE induces mutations in the lungs of rats [Sato et al., 2000] and mice (this study). In the lungs of *gpt* delta mice treated with inhalation of 3 mg m^{-3} DE for 12 weeks, the MF was 3.2-fold higher than the control group (1.90×10^{-5} vs. 0.59×10^{-5}). In contrast, the MF in the lungs of Big Blue® rats treated with inhalation of 6 mg m^{-3} DE for 4 weeks was 4.8-fold higher than the control group (4.25×10^{-5} vs. 0.88×10^{-5}) [Sato et al., 2000]. Similarly, the MF in lungs in *gpt* delta rats treated with inhalation of 3 mg m^{-3} DE for 12 weeks was 4.1-fold higher than the control group (2.70×10^{-5} vs. 0.65×10^{-5}, our unpublished results). Thus, the MF induced by inhalation of DE would appear to be lower in mice than rats. Relative to rats, the lower mutagenicity of DE in mice may be a cause of reduced tumor induction in the lungs of DE-treated mice [Mauderly et al., 1996].

We showed that MF was dependent upon the amount of DEP (from 0–0.5 mg [Table II]). The mutagenic potency (MF mg^{-1}) of DEP extract (5.6×10^{-5} mg^{-1}) was twice that of DEP (2.7×10^{-5} mg^{-1}). As DEP extract accounts for ca. 50% of the weight of DEP, this result may indicate that the mutagenicity of DEP is derived from compounds in the extract. However, unexpectedly, we found no significant difference between the MFs induced by inhalation of 1 and 3 mg m^{-3} DE for 12 weeks (Table I), whereas the DEP burden in mouse lung is known to increase linearly with respect to the period of inhalation (6–18 months) or the concentration of DE (0.35, 3.5, and 7 mg m^{-3}) [Mauderly et al., 1996]. Based on the findings of Mauderly et al. [1996], the lung burden under our exposure conditions was estimated at 0.4 and 1.3 mg DEP following 12 weeks of exposure to 1 and 3 mg m^{-3}, respectively. This estimate was obtained by correcting for the duration of exposure and DE concentration (our conditions were 12 hr day^{-1}, 7 day $week^{-1}$ vs. 7 hr day^{-1}, 5 day $week^{-1}$ for Mauderly et al. [1996]). The differences observed between the experiments may indicate that at higher DEP lung burdens, incorporation of mutagens into pulmonary tissue does not depend on the amount of DEP deposited. In fact, analysis of data

TABLE IV. DNA Sequence Analysis of *gpt* Mutations Obtained From the Lungs of DE, DEP-Treated, and Control Mice

Type of mutation	Nucleotide	Sequence change		Amino acid change	Number				
					Control (DE)	DE	Control (DEP and DEP extract)	DEP	DEP extract
Base substitution									
Transition									
G:C → A:T	3	atG → atA		Met → Ile				1	
	26	tGg → tAg		Trp → Stop		2[a]			
	27	tgG → tgA		Trp → Stop	1				
	64	Cga → Tga	CpG	Arg → Stop	6[c]	8[b]		4[b]	7[d]
	82	Caa → Taa		Gln → Stop		1			1
	87	tgG → tgA		Trp → Stop	1	1		1	1
	92	gGc → gAc		Gly → Asp		1			
	110	cGt → cAt	CpG	Arg → His	5[c]	14[d]	3[a]	16[e]	15[f]
	113	gGc → gAc		Gly → Asp		1			
	115	Ggt → Agt	CpG	Gly → Ser	1	6[d]	1	4[b]	3[b]
	116	gGt → gAt		Gly → Asp	1	1	2		2[a]
	128	gGt → gAt		Gly → Asp		1			
	145	Gaa → Aaa		Glu → Lys	1			1	1
	176	tGt → tAt		Cys → Tyr		1			
	185	aGc → aAc		Ser → Asn		3[b]			
	262	Gat → Aat		Asp → Asn	1			1	
	274	Gat → Aat		Asp → Asn	1			2[a]	1
	281	gGt → gAt		Gly → Asp		1			
	287	aCt → aTt		Thr → Ile	1				
	290	gCg → gTg	CpG	Ala → Val	1				
	346	Ccg → Tcg		Pro → Ser					1
	350	gCt → gTt		Ala → Val				1	1
	391	Caa → Taa		Gln → Stop		2[a]		1	1
	401	tGg → tAg		Trp → Stop		6[b]	1	3[b]	
	402	tgG → tgA		Trp → Stop		4[b]			
	406	Gaa → Aaa		Glu → Lys		6[a]			1
	409	Cag → Tag		Gln → Stop				1	
	416	tGg → tAg		Trp → Stop				1	
	417	tgG → tgA		Trp → Stop				7[a]	
	418	Gat → Aat		Asp → Asn	2[a]	10[e]		5[b]	2
	451	Ggt → Agt	CpG	Gly → Ser				1	
A:T → G:C	17	aTc → aCc		Ile → Thr		1			
	41	aTc → aCc		Ile → Thr			1		
	56	cTc → cCc		Leu → Pro	1	2[a]			3[a]
	146	gAa → gGa		Glu → Gly					1
	181	Tcc → Ccc		Ser → Pro					1
	269	cTg → cCg		Leu → Pro	1				1
	400	Tgg → Cgg		Trp → Arg	1				
	415	Tgg → Cgg		Trp → Arg					1
	419	gAt → gGt		Asp → Gly	1			1	
Transversion									
G:C → T:A	3	atG → atT		Met → Ile				1	
	7	Gaa → Taa	CpG	Glu → Stop	1			2	2[a]
	15	taC → taA		Tyr → Stop					1
	26	tGg → tTg		Trp → Leu				1	
	59	gCa → gAa		Ala → Glu		1			
	79	Gaa → Taa		Glu → Stop					1
	107	aGc → aTc		Ser → Ile	1				
	115	Ggt → Tgt	CpG	Gly → Cys	1				
	116	gGt → gTt		Gly → Val		1		1	
	140	gCg → gAg	CpG	Ala → Glu		1	1	1	
	143	cGt → cTt	CpG	Arg → Leu					2[a]
	145	Gaa → Taa		Glu → Stop			1	1	1
	176	tGt → tTt		Cys → Phe				2[a]	2[a]
	182	tCc → tAc		Ser → Tyr				1	
	185	aGc → aTc		Ser → Ile		1			
	189	taC → taA	CpG	Tyr → Stop	3			1	

TABLE IV. *Continued*

Type of mutation	Nucleotide	Sequence change		Amino acid change	Number				
					Control (DE)	DE	Control (DEP and DEP extract)	DEP	DEP extract
	190	Gat → Tat	CpG	Asp → Tyr				1	
	205	Cgc → Agc	CpG	Arg → Ser				1	
	208	Gag → Tag	CpG	Glu → Stop				1	
	220	Ctg → Atg		Leu → Met					1
	230	gCa → gAa		Ala → Glu				1	
	244	Gaa → Taa	CpG	Glu → Stop				1	
	262	Gat → Tat		Asp → Tyr				1	
	268	Ctg → Atg		Leu → Met				1	
	274	Gat → Tat		Asp → Tyr	1				2[a]
	287	aCt → aAt		Thr → Asn	1				1
	304	Gaa → Taa		Glu → Stop		2[a]		1	
	313	Cca → Aca		Pro → Thr				1	
	319	Gcg → Tcg		Ala → Ser		1			
	320	gCg → gAg	CpG	Ala → Glu		1	1	1	1
	346	Ccg → Acg		Pro → Thr					1
	389	cCg → cAg	CpG	Pro → Gln					1
	401	tGg → tTg		Trp → Leu	1	2[a]		1	1
	402	tgG → tgT		Trp → Cys		3[a]		1	
	406	Gaa → Taa		Glu → Stop	7[d]	3[a]		4[b]	4[c]
	409	Cag → Aag		Gln → Lys		2	1	1	
	411	caG → caT		Gln → His				1	
	412	Ccg → Acg		Pro → Thr					1
	413	cCg → cAg	CpG	Pro → Gln	1				
	418	Gat → Tat		Asp → Tyr		3[a]		6[a]	1
G:C → C:G	6	agC → agG	CpG	Ser → Arg		2		1	
	46	Gca → Cca		Ala → Pro		1			
	112	Ggc → Cgc		Gly → Arg					1
	115	Ggt → Cgt	CpG	Gly → Arg		2[a]			1
	125	cCg → cGg	CpG	Pro → Arg					1
	127	Ggt → Cgt		Gly → Arg	1			1	
	130	Gcg → Ccg		Ala → Pro				1	
	139	Gcg → Ccg		Ala → Pro		1			
	145	Gaa → Caa		Glu → Gln					1
	185	aGc → aCc		Ser → Thr					2
	190	Gat → Cat	CpG	Asp → His					1
	262	Gat → Cat		Asp → His				1	
	280	Ggt → Cgt	CpG	Gly → Arg					1
	281	gGt → gCt		Gly → Ala				1	
	290	gCg → gGg	CpG	Ala → Gly			1		
	295	Gcg → Ccg		Ala → Pro					1
	340	Gca → Cca	CpG	Ala → Pro		1			1
	402	tgG → tgC		Trp → Cys				1	
	413	cCg → cGg	CpG	Pro → Arg					1
	442	Cca → Gca		Pro → Ala			1		
	443	cCa → cGa		Pro → Arg				1	1
A:T → T:A	8	gAa → gTa		Glu → Val				1	
	10	Aaa → Taa		Lys → Stop				1	
	11	aAa → aTa		Lys → Ile				1	
	12	aaA → aaT		Lys → Asn					1
	83	cAa → cTa		Gln → Leu				1	
	134	tTa → tAa		Leu → Stop		1			
	146	gAa → gTa		Glu → Val		1			
	164	gTc → gAc		Val → Asp				1	
	187	Tac → Aac		Tyr → Asn			1		
	214	Aaa → Taa		Lys → Stop				1	
	260	aTt → aAt		Ile → Asn	1				
	311	tAt → tTt		Tyr → Phe					1
	365	gTt → gAt		Val → Asp	1				
	419	gAt → gTt		Asp → Val		4			

TABLE IV. *Continued*

Type of mutation	Nucleotide	Sequence change	Amino acid change	Number				
				Control (DE)	DE	Control (DEP and DEP extract)	DEP	DEP extract
A:T → C:G	10	Aaa → Caa	Lys → Gln					1
	17	aTc → aGc	Ile → Ser				1	
	56	cTc → cGc	Leu → Arg				4	
	106	Agc → Cgc	Ser → Arg				1	1
	188	tAc → tCc	Tyr → Ser				1	
	312	taT → taG	Tyr → Stop					1
	345	aaA → aaC	Lys → Asn					1
	419	gAt → gCt	Asp → Ala				1	
Deletion								
−1 base	8–12	gAAAAAt → gAAAAt		4[b]				1
	32	aTg → ag					1	
	34–35	gTTg → gTg			1	1		
	37	gCa → ga			2[a]			
	83–84	cAAt → cAt						1
	97	tAt → tt						1
	115–116	cGGt → cGt			1			
	137	cTg → cg			1			
	170–171	aCCg → aCg			1			
	176	tGt → tt		1				
	201–202	aCCa → aCa		1				
	237	gCg → gg					1	1
	272	gTg → gg			1			
	315–318	cAAAAg → cAAAg					1	
	321	cGc → cc			1			
	352–353	tGGt → tGt			1			
	369	aTg → ag					1	
	407–408	gAAc → gAc						1
	412–413	gCCg → gCg			1			
	416–418	tGGGa → tGGa		2[a]			1	2[a]
	426	gCg → gg			1			
	431	gTa → ga						1
	442–443	gCCa → gCa		1	1			
	444–445	cAAt → cAt					2[a]	1
	449–450	tCCg → tCg						1
	451–452	cGGt → cGt					5[d]	1
>2	97–111	tATTGCCGTAAGCCGTg → tg						1
	149–165	cTGGGTATTCGTCATGTCg → cg						1
	158–170	cGTCATGTCGATACc → cc					1	
	170–171	aCCg → ag			1			
	177–196	gTATTTCCAGCTACGATCACGa → ga			1			
	226–227	aCGc → ac			1			
	250–255	cTTCATCg → cg					1	
	252–254	tCATc → tc			1			
	262–273	tGATGACCTGGTGg → tg			1			
	292–320	gGTTGCGATTCGTGAAAT-GTATCCAAAAGCg → gg					1	
	375–377	aTGTt → at					1	
Insertion	8–12	gAAAAAt → gAAAAAAt			1			
	35	tg → tCg					1	
	83–84	cAAt → cAAAt					1	
	120–121	tGGt → tGGGt						2
	269	cTg → cTTg			1			
	301	cg → cGTGAAATg					1	
	312	tc → tGc					1	
Other	46–47	tGCa → tAGa			1			
	401–402	tGGa → tAAa						1

[a]Mutations found in 2 different mice.
[b]Mutations found in 3 different mice.
[c]Mutations found in 4 different mice.
[d]Mutations found in 5 different mice.
[e]Mutations found in 7 different mice.
[f]Mutations found in 8 different mice.

TABLE V. Classification of *gpt* Mutations From the Lungs of Control, DEP-, and DEP Extract-Treated Mice

Type of mutation in *gpt*	Control		DEP		DEP extract		DEP (mg)						DEP extract (mg)					
			All		All		0.125		0.25		0.5		0.05		0.1		0.2	
	Number	%	Number	%	Number	%	Number	%	Number	%	Number	%	Number	%	Number	%	Number	%
Base substitution																		
Transition																		
G:C → A:T (CpG site)	7 (4)	44	50 (25)	39	37 (25)	37	18 (13)	46	20 (11)	43	12 (1)	29	10 (6)	30	12 (9)	35	15 (10)	44
A:T → G:C	1	6	1	1	7	7	0	0	1	2	0	0	3	9	2	6	2	6
Transversion																		
G:C → T:A	4	25	35	28	23	23	9	23	10	21	16	39	7	21	8	24	8	24
G:C → C:G	2	13	7	6	12	12	4	10	1	2	2	5	8	24	1	3	3	9
A:T → T:A	1	6	6	5	2	2	2	5	2	4	2	5	0	0	2	6	0	0
A:T → C:G	0	0	8	6	4	4	1	3	3	6	4	10	0	0	2	6	2	6
Deletion																		
−1	1	6	12	9	11	11	3	8	6	13	3	7	2	6	5	15	4	12
>2	0	0	4	3	2	2	1	3	3	6	0	0	1	3	1	3	0	0
Insertion	0	0	4	3	2	2	1	3	1	2	2	5	2	6	0	0	0	0
Other	0	0	0	0	1	1	0	0	0	0	0	0	0	0	1	3	0	0
Total	*16*	*100*	*127*	*100*	*101*	*100*	*39*	*100*	*47*	*100*	*41*	*100*	*33*	*100*	*34*	*100*	*34*	*100*

reported by Sun et al. [1984], Bond et al. [1986], and Yu et al. [1991] demonstrated that in the lungs the concentration of organic compounds released from DEP reaches a steady state at an early phase of exposure. Alternatively, DE-induced mutagenesis may occur via a mechanism that is easily saturated, such as DNA adduct formation, generation of reactive oxygen species, or inflammation. Further studies are required to examine whether mutagenicity is increased in DNA repair system-deficient mice by DE treatment.

The IARC classification categorizes DE as a Group 2A substance and DEP contains various potent mutagenic PAHs and nitro-PAHs such as B[*a*]P and DNPs. To assess the health risks of DE, we attempted to identify components responsible for mutagenicity in the lungs of *gpt* delta mice. As mentioned above, intratracheal instillation of DEP or DEP extract increased the MF linearly, depending on the dosage (Table II). Inhalation of DE and instillation of DEP and DEP extract induced mutations at hotspots in *gpt* (mutation loci identified from three or more mice at nucleotide numbers 64, 110, 115, 185, 401, 402, and 418 (DE inhalation); 64, 110, 115, 401, and 418 (DEP); and 64, 110, and 115 (DEP extract); Table IV). Analysis of sequences adjacent to the mutated guanine bases (Fig. 1) identified the sequences G*G*A, T*G*A, C*G*G, and C*G*T as major targets for mutation. These results indicate that DE, DEP, and DEP extract targeted the same nucleotide sequences on *gpt*, producing DNA adducts. According to the Environmental Health Criteria 171 [International Programme on Chemical Safety, 1996], the carbon black in DEP and DEP extract contributes to the carcinogenicity of DE. Our study demonstrates that DEP extract exerts potent in vivo mutagenicity in the lung and that the mutation hotspots and target sequences are similar for mice that are treated with inhalation of DE or instillation of DEP and DEP extract. These observations suggest that compounds in the DEP extract induce mutations in the lung.

We compared the mutation spectra caused by the different treatments and observed that following inhalation of DE, G:C → A:T transitions were the predominant mutation in *gpt* delta mice (Table III). This result confirms previous observations in the lungs of Big Blue® rats [Sato et al., 2000]. In the lungs of DEP and DEP extract-instilled mice, G:C → A:T transitions were also the major base substitutions but G:C → T:A transversions were induced at a higher frequency than by inhalation of DE (Table V). We expected that G:C → T:A transversions would be the predominant base substitution induced by DE, since B[*a*]P is considered to be a major mutagenic component in DE, and such transversions are a common B[*a*]P-induced mutation in the mouse lung [Hashimoto et al., 2005]. As G:C → T:A transversions were induced by DEP- and DEP extract-instillation, it is likely that B[*a*]P contributes partly to DE-induced mutagenesis. However, to understand the mechanism underlying DE-induced carcinogenesis, the mutagen responsible for G:C → A:T transitions must be identified.

A number of mutagenic compounds have been identified in DEP using a Salmonella assay [Jeffrey et al., 1990; Tokiwa et al., 1993], and Salmeen et al. [1984] suggested that mono- and dinitro-PAHs such as 1,3-, 1,6- and 1,8-DNP may account for between 30 and 40% of the mutagenic activity. We have shown that intratracheal instillation of 1,6-DNP into the lungs of *gpt* delta mice [Hashimoto et al., 2005, 2006] induced mainly G:C → A:T transitions but not G:C → T:A transversions. In addition, the mutation

hotspots induced by DE inhalation were similar to those induced by 1,6-DNP [Hashimoto et al., 2006] but not by B[*a*]P [Hashimoto et al., 2005]. These results suggest that 1,6-DNP and related compounds are likely to be among the main contributors to mutagenesis induced by DE inhalation. Further studies are required to identify all the major mutagens in DE and to understand the mechanisms of mutagenesis induced by DE inhalation.

ACKNOWLEDGMENTS

We thank Dr. Kazuichi Hayakawa (Kanazawa University) for providing DEP extract, and Drs. Hiroaki Shiraishi, Michi Matsumoto, and Wakae Maruyama (NIES) for their support and advice.

REFERENCES

Adams WT, Skopek TR. 1987. Statistical test for the comparison of samples from mutational spectra. J Mol Biol 194:391–396.

Arai T, Kelly VP, Komoro K, Minowa O, Noda T, Nishimura, S. 2003. Cell proliferation in liver of *mmh/ogg1*-deficient mice enhances mutation frequency because of the presence of 8-hydroxyguanine in DNA. Cancer Res 63:4287–4292.

Bond JA, Sun JD, Medinsky MA, Jones RK, Yeh HC. 1986. Deposition, metabolism, and excretion of 1-[^{14}C]nitropyrene and 1-[^{14}C]nitropyrene coated on diesel exhaust particles as influenced by exposure concentration. Toxicol Appl Pharmacol 85:102–117.

Brightwell J, Fouillet X, Cassano-Zoppi AL, Gatz R, Duchosal F. 1986. Neoplastic and functional changes in rodents after chronic inhalation of engine exhaust emissions. Dev Toxicol Environ Sci 13:471–485.

Cariello NF, Piegorsch WW, Adams WT, Skopek TR. 1994. Computer program for the analysis of mutational spectra: Application to *p*53 mutations. Carcinogenesis 15:2281–2285.

Gallagher J, Heinrich U, George M, Hendee L, Phillips DH, Lewtas J. 1994. Formation of DNA adducts in rat lung following chronic inhalation of diesel emissions, carbon black and titanium dioxide particles. Carcinogenesis 15:1291–1299.

Harris JE. 1983. Diesel emissions and lung cancer. Risk Anal 3:83–100.

Hashimoto AH, Amanuma K, Hiyoshi K, Takano H, Masumura K, Nohmi T, Aoki Y. 2005. *In vivo* mutagenesis induced by benzo[*a*]pyrene instilled into the lung of *gpt* delta transgenic mice. Environ Mol Mutagen 45:365–373.

Hashimoto AH, Amanuma K, Hiyoshi K, Takano H, Masumura K, Nohmi T, Aoki Y. 2006. *In vivo* mutagenesis in the lungs of *gpt* delta transgenic mice treated intratracheally with 1,6-dinitropyrene. Environ Mol Mutagen 47:277–283.

Hayakawa K, Nakamura A, Terai N, Kizu R, Ando K. 1997. Nitroarene concentrations and direct-acting mutagenicity of diesel exhaust particulates fractionated by silica-gel column chromatography. Chem Pharm Bull 45:1820–1822.

Hill KA, Halangoda A, Heinmoeller PW, Gonzalez K, Chitaphan C, Longmate J, Scaringe WA, Wang JC, Sommer SS. 2005. Tissue-specific time courses of spontaneous mutation frequency and deviations in mutation pattern are observed in middle to late adulthood in Big Blue mice. Environ Mol Mutagen 45:442–454.

Ichinose T, Yajima Y, Nagashima M, Takenoshita S, Nagamachi Y, Sagai M. 1997. Lung carcinogenesis and formation of 8-hydroxydeoxyguanosine in mice by diesel exhaust particles. Carcinogenesis 18:185–192.

International Programme on Chemical Safety. 1996. Diesel fuel and exhaust emissions. Environmental Health Criteria 171. Geneva: World Health Organization.

Iwai K, Higuchi K, Udagawa T, Ohtomo K, Kawabata Y. 1997. Lung tumor induced by long-term inhalation or intratracheal instillation of diesel exhaust particles. Exp Toxicol Pathol 49:393–401.

Iwai K, Adachi S, Takahashi M, Möller L, Udagawa T, Mizuno S, Sugawara I. 2000. Early oxidative DNA damages and late development of lung cancer in diesel exhaust-exposed rats. Environ Res 84:255–264.

Jeffrey AM, Santella RM, Wong D, Hsieh LL, Heisig V, Doskocil G, Ghayourmanesh S. 1990. Metabolic activation of nitropyrenes and diesel particulate extracts. Res Rep Health Eff Inst 34:1–30.

Masumura K, Matsui K, Yamada M, Horiguchi M, Ishida K, Watanabe M, Wakabayashi K, Nohmi T. 2000. Characterization of mutations induced by 2-amino-1-methyl-6-phenylimidazo[4,5-*b*]pyridine in the colon of *gpt* delta transgenic mouse: Novel G:C deletions beside runs of identical bases. Carcinogenesis 21:2049–2056.

Masumura K, Horiguchi M, Nishikawa A, Umemura T, Kanki K, Kanke Y, Nohmi T. 2003. Low dose genotoxicity of 2-amino-3,8-dimethylimidazo[4,5-*f*] quinoxaline (MeIQx) in *gpt* delta transgenic mice. Mutat Res 541:91–102.

Mauderly JL, Jones RK, Griffith WC, Henderson RF, McClellan RO. 1987. Diesel exhaust is a pulmonary carcinogen in rats exposed chronically by inhalation. Fundam Appl Toxicol 9:208–221.

Mauderly JL, Banas DA, Griffith WC, Hahn FF, Henderson RF, McClellan RO. 1996. Diesel exhaust is not a pulmonary carcinogen in CD-1 mice exposed under conditions carcinogenic to F344 rats. Fundam Appl Toxicol 30:233–242.

Muranaka M, Suzuki S, Koizumi K, Takafuji S, Miyamoto T, Ikemori R, Tokiwa H. 1986. Adjuvant activity of diesel-exhaust particulates for the production of IgE antibody in mice. J Allergy Clin Immunol 77:616–623.

Nagashima M, Kasai H, Yokota J, Nagamachi Y, Ichinose T, Sagai M. 1995. Formation of an oxidative DNA damage, 8-hydroxydeoxyguanosine, in mouse lung DNA after intratracheal instillation of diesel exhaust particles and effects of high dietary fat and β-carotene on this process. Carcinogenesis 16:1441–1445.

Nikula KJ, Snipes MB, Barr EB, Griffith WC, Henderson RF, Mauderly JL. 1995. Comparative pulmonary toxicities and carcinogenicities of chronically inhaled diesel exhaust and carbon black in F344 rats. Fundam Appl Toxicol 25:80–94.

Nohmi T, Katoh M, Suzuki H, Matsui M, Yamada M, Watanabe M, Suzuki M, Horiya N, Ueda O, Shibuya T, Ikeda H, Sofuni T. 1996. A new transgenic mouse mutagenesis test system using Spi$^-$ and 6-thioguanine selections. Environ Mol Mutagen 28:465–470.

Nohmi T, Suzuki T, Masumura K. 2000. Recent advances in the protocols of transgenic mouse mutation assays. Mutat Res 455:191–215.

Ono T, Ikehata H, Pithani VP, Uehara Y, Chen Y, Kinouchi Y, Shimosegawa T, Hosoi Y. 2004. Spontaneous mutations in digestive tract of old mice show tissue-specific patterns of genomic instability. Cancer Res 64:6919–6923.

Østby L, Engen S, Melbye A, Eide I. 1997. Mutagenicity testing of organic extracts of diesel exhaust particles after fractionation and recombination. Arch Toxicol 71:314–319.

Rivedal E, Myhre O, Sanner T, Eide I. 2003. Supplemental role of the Ames mutation assay and gap junction intercellular communication in studies of possible carcinogenic compounds from diesel exhaust particles. Arch Toxicol 77:533–542.

Sagai M, Saito H, Ichinose T, Kodama M, Mori Y. 1993. Biological effects of diesel exhaust particles. I. *In vitro* production of superoxide and *in vivo* toxicity in mouse. Free Radic Biol Med 14:37–47.

Salmeen IT, Pero AM, Zator R, Schuetzle D, Riley TL. 1984. Ames assay chromatograms and the identification of mutagens in diesel particle extracts. Environ Sci Technol 18:375–382.

Sato H, Sone H, Sagai M, Suzuki KT, Aoki Y. 2000. Increase in mutation frequency in lung of Big Blue rat by exposure to diesel exhaust. Carcinogenesis 21:653–661.

Sato H, Suzuki KT, Sone H, Yamano Y, Kagawa J, Aoki Y. 2003. DNA-adduct formation in lungs, nasal mucosa, and livers of rats exposed to urban roadside air in Kawasaki City, Japan. Environ Res 93:36–44.

Sun JD, Wolff RK, Kanapilly GM, McClellan RO. 1984. Lung retention and metabolic fate of inhaled benzo(*a*)pyrene associated with diesel exhaust particles. Toxicol Appl Pharmacol 73:48–59.

Suzuki T, Itoh S, Nakajima M, Hachiya N, Hara T. 1999. Target organ and time-course in the mutagenicity of five carcinogens in Muta-Mouse: A summary report of the second collaborative study of the transgenic mouse mutation assay by JEMS/MMS. Mutat Res 444:259–268.

Takano H, Ichinose T, Miyabara Y, Shibuya T, Lim HB, Yoshikawa T, Sagai M. 1998. Inhalation of diesel exhaust enhances allergen-related eosinophil recruitment and airway hyperresponsiveness in mice. Toxicol Appl Pharmacol 150:328–337.

Takano H, Yanagisawa R, Ichinose T, Sadakane K, Inoue K, Yoshida S, Takeda K, Yoshino S, Yoshikawa T, Morita M. 2002. Lung expression of cytochrome P450 1A1 as a possible biomarker of exposure to diesel exhaust particles. Arch Toxicol 76:146–151.

Thybaud V, Dean S, Nohmi T, de Boer J, Douglas GR, Glickman BW, Gorelick NJ, Heddle JA, Heflich RH, Lambert I, Martus HJ, Mirsalis JC, Suzuki T, Yajima N. 2003. *In vivo* transgenic mutation assays. Mutat Res 540:141–151.

Tokiwa H, Sera N, Horikawa K, Nakanishi Y, Shigematu N. 1993. The presence of mutagens/carcinogens in the excised lung and analysis of lung cancer induction. Carcinogenesis 14:1933–1938.

Valberg PA, Crouch EAC. 1999. Meta-analysis of rat lung tumors from lifetime inhalation of diesel exhaust. Environ Health Perspect 107:693–699.

Yu CP, Yoon KJ, Chen YK. 1991. Retention modeling of diesel exhaust particles in rats and humans. J Aerosol Med 4:79–115.

Accepted by—
I. Lambert

Available online at www.sciencedirect.com
ScienceDirect
Mutation Research xxx (2008) xxx–xxx
ELSEVIER
Fundamental and Molecular Mechanisms of Mutagenesis
www.elsevier.com/locate/molmut
Community address: www.elsevier.com/locate/mutres

Differential effects of low- and high-dose X-rays on *N*-ethyl-*N*-nitrosourea-induced mutagenesis in thymocytes of B6C3F1 *gpt*-delta mice

Kazumi Yamauchi [a], Shizuko Kakinuma [a], Satomi Sudo [a,b], Seiji Kito [a], Yuki Ohta [a], Takehiko Nohmi [c], Ken-ichi Masumura [c], Mayumi Nishimura [a], Yoshiya Shimada [a,*]

[a] *Experimental Radiobiology for Children's Health Research Group, Research Center for Radiation Protection, National Institute of Radiological Sciences, 4-9-1, Anagawa, Inage-ku, Chiba 263-8555, Japan*
[b] *Department of Biomolecular Science, Faculty of Science, Toho University, 2-2-1, Miyama, Funabashi, Chiba 274-8510, Japan*
[c] *Division of Genetics and Mutagenesis, National Institute of Health Sciences, 1-18-1, Kamiyoga, Setagaya-ku, Tokyo 158-850, Japan*

Received 19 June 2007; received in revised form 30 November 2007; accepted 6 December 2007

Abstract

Carcinogenesis in humans is thought to result from exposure to numerous environmental factors. Little is known, however, about how these different factors work in combination to cause cancer. Because thymic lymphoma is a good model of research for combined exposure, we examined the occurrence of mutations in thymic DNA following exposure of B6C3F1 *gpt*-delta mice to both ionizing radiation and *N*-ethyl-*N*-nitrosourea (ENU). Mice were exposed weekly to whole body X-irradiation (0.2 or 1.0 Gy), ENU (200 ppm) in the drinking water, or X-irradiation followed by ENU treatment. Thereafter, genomic DNA was prepared from the thymus and the number and types of mutations in the reporter transgene *gpt* was determined. ENU exposure alone increased mutant frequency by 10-fold compared to untreated controls and over 80% of mutants had expanded clonally. X-irradiation alone, at either low or high dose, unexpectedly, reduced mutant frequency. Combined exposure to 0.2 Gy X-rays with ENU dramatically decreased mutant frequency, specifically G:C to A:T and A:T to T:A mutations, compared to ENU treatment alone. In contrast, 1.0 Gy X-rays enhanced mutant frequency by about 30-fold and appeared to accelerate clonal expansion of mutated cells. In conclusion, repeated irradiation with 0.2 Gy X-rays not only reduced background mutation levels, but also suppressed ENU-induced mutations and clonal expansion. In contrast, 1.0 Gy irradiation in combination with ENU accelerated clonal expansion of mutated cells. These results indicate that the mode of the combined mutagenic effect is dose dependent.

Keywords: Combined genotoxic effect; *gpt*-delta mouse; *N*-Ethyl-*N*-nitrosourea; Radiation; Clonal expansion

1. Introduction

Humans are continuously and simultaneously exposed to numerous environmental mutagens. It is important, therefore, to determine the dose–effect relationship of combined exposure when assessing human health risks. Mutagenic DNA damage arises from interaction of DNA with a myriad of endogenous and exogenous agents [1]. Ionizing radiation induces DNA strand breaks and base modifications, directly or indirectly via reactive oxygen species. Such DNA damages result in base substitutions, insertions and deletions. Thus, the recent increase in the utilization of, and hence chance for exposure to, medical ionizing radiation has raised an aspect of social concern. Alkylating agents also modify DNA, thereby inducing base substitutions that lead to point mutations [2,3]. These agents are found in plants, food, cigarette smoke, fuel combustion products, and commonly used industrial solvents. In addition, ionizing radiation and some alkylating agents are used for cancer chemotherapy. *N*-Ethyl-*N*-nitrosourea (ENU) is a potent alkylating mutagen and carcinogen that induces G:C to A:T transitions,

* Corresponding author. Tel.: +81 43 206 3200; fax: +81 43 206 4138.
E-mail address: y_shimad@nirs.go.jp (Y. Shimada).

0027-5107/$ – see front matter © 2008 Elsevier B.V. All rights reserved.
doi:10.1016/j.mrfmmm.2007.12.001

A:T to G:C transitions and A:T to T:A transversions *in vivo* [4–8]. Since ionizing radiation and alkylating agents are widely distributed and utilized, understanding their toxicity and the cellular response mechanism(s) is important. Occasionally, we are exposed to these agents simultaneously in the environment or for therapeutic reasons. However, currently available data are not sufficient to delineate the mode and the mechanism of combined action of these agents.

The combined effect of radiation and alkylating agents has been examined in animal tumor models, including thymic lymphomas, brain tumors, mammary tumors and colon tumors [9–12]. Thymic lymphoma (TL) is an excellent model for human T-cell acute lymphoblastic leukemia and has been used for the study of radiation carcinogenesis. Concomitant exposure to butylnitrosourea and X-rays for 12 weeks accelerates the development of thymic lymphoma in BDF1 mice, in a manner dependent on the dose of radiation [9,13]. Irradiation 2–5 weeks before methylnitrosourea exposure accelerates thymic lymphoma development [13]. Irradiation for 5 days, but not 30 days, before administrating ENU treatment enhances lymphomagenesis [9].

DNA mutations play a central role in carcinogenesis. The frequency and type of mutations that result from combined treatment may shed light on the molecular mechanism(s) underlying the carcinogenic effects of combined exposure to alkylating agents and radiation. In order to delineate such mechanisms, we have examined the occurrence of mutations in thymic cells of B6C3F1 (*gpt*+/−) mice after combined exposure to X-rays and ENU. Repeated exposure to high-dose X-rays (1.0 Gy) followed by ENU increased the frequency of mutants and facilitated clonal expansion of mutated cells. However, unexpectedly, when low-dose X-rays (0.2 Gy) preceded ENU, mutant frequency was reduced primarily due to a decrease in G:C to A:T and A:T to T:A mutations. This is the first report, to our knowledge, that provides a new evidence on the mode and mechanism of combined exposure, which clearly differs between low and high dose of radiation.

2. Materials and methods

2.1. Mice

Male C3H/He mice were purchased from Charles River Laboratories (Kanagawa, Japan). Female *gpt*-delta C57BL/6J mice carrying approximately 80 copies of λEG10 DNA in haploid genome were obtained from Japan SLC (Shizuoka, Japan) [14]. Mice were housed five to a cage in a room maintained at 23 ± 2 °C and 50 ± 10% humidity, with a 12 h dark–light cycle. All mice were fed standard laboratory diet MB-1 (Funabashi Farm Co., Ltd., Chiba, Japan) and water *ad libitum*.

2.2. Chemicals

ENU (CAS No. 759-73-9) was purchased from Nakarai Tesque (Kyoto, Japan). Reagents for M9 buffer preparation were purchased from Nakarai Tesque and Wako Pure Chemical Industries (Osaka, Japan). Dimethyl sulfoxide and 6-thioguanine (6-TG) were purchased from Sigma Chemical Co. (St. Louis, MO, USA). Chloramphenicol (Cm) was purchased from Wako Pure Chemical Industries. Bacto yeast extract, Bacto tryptone and Bacto agar were obtained from Difco (Franklin Lakes, NJ, USA).

2.3. Irradiation

X-ray irradiation was performed using a Pantak HF-320 machine (PANTAK Ltd., East Haven, CT, USA) at 200 kV, 20 mA, and a dose rate of 0.7 Gy/min.

2.4. Combined X-ray exposure and ENU treatment

Mice (4–5 weeks old) were exposed weekly to 0.2 or 1.0 Gy X-rays for 4 consecutive weeks, because this X-ray exposure method is the most leukemogenic [15]. ENU was dissolved in reverse osmosis water (Elix UV10, Millipore, Bedford, MA) at pH 6.0 to prepare 200 ppm (1.17 mM) solution. To avoid degradation, ENU solution was administered in drinking water in brown bottle immediately after preparation. Freshly prepared ENU solution was exchanged on every Monday, Wednesday, Friday and Saturday during treatment. The amount of ENU solution up-taken was approximately 3 ml per mouse per day. For combined exposures, X-ray irradiation at 0.2 or 1.0 Gy for 4 consecutive weeks was followed by 4 weeks of ENU treatment (Fig. 1). Four weeks after the end of ENU treatment, mice were sacrificed and thymuses were collected and frozen immediately in liquid nitrogen, then stored at −80 °C until use. These animal experiments were conducted in compliance with guidelines for animal experiments of the National Institute of Radiological Sciences for the care and use of laboratory animals.

2.5. Genomic DNA extraction and in vitro packaging

The thymuses (20 mg) were homogenized in a Dounce homogenizer (Kontes, Vineland, NJ, USA) and genomic DNA was isolated using the RecoverEase DNA isolation kit (Stratagene, La Jolla, CA, USA). Transpack Packaging Extract (Stratagene, La Jolla, CA, USA) was used to rescue λEG10 phages from genomic DNA (10 μl) isolated from the thymus.

2.6. gpt mutation assay

The *gpt* mutagenesis assay was performed on five mice per group according to methods previously described [16]. Briefly, λEG10 phage was incubated with *E. coli* YG6020 at 37 °C for 20 min. After incubation, *E. coli* was incubated at 37 °C with vigorous agitation for 30 min. *E. coli* was mixed with 0.6% molten soft agar with or without 6-TG and the entire contents poured onto the M9 + Cm + 6-TG or M9 + Cm plates and incubated at 37 °C for 3 or 2 days. After incubation, colonies were counted and on M9 + Cm + 6-TG plates were subject to colony PCR for *gpt* gene. At least three independent experiments were performed per mouse.

Mutant frequency was calculated by dividing the number of colonies growing on M9 + Cm + 6-TG plates by the number of colonies growing on M9 + Cm plates.

Recurrent mutations derived from the same tissue of a single animal could be the result of clonal expansion that occurred early after mutagen treatment. When multiple identical mutations were recovered from an individual mouse, the



Fig. 1. Experimental design for *gpt* mutation analysis of thymic DNA from mice treated with X-ray irradiation, ENU or a combination of the two. Mice were exposed to X-rays weekly. ENU was administered at a concentration of 200 ppm in drinking water.

Please cite this article in press as: K. Yamauchi, et al., Differential effects of low- and high-dose X-rays on *N*-ethyl-*N*-nitrosourea-induced mutagenesis in thymocytes of B6C3F1 *gpt* delta mice, Mutat. Res./Fundam. Mol. Mech. Mutagen. (2008), doi:10.1016/j.mrfmmm.2007.12.001

data were corrected for any clonal expressions by counting just the mutation as defined by independent mutation [17,18]. *Mutation frequency* was calculated as the ratio of calculated total independent mutants to the total number of colonies growing on M9 + Cm plates. Mutational common hot spots were defined as sites where the same mutation was observed in three or more mice from the same group. Clonality was calculated as the ratio of clonal (total – independent) mutations to the total mutations [19,20].

2.7. PCR and DNA sequencing analysis of gpt

A 739-bp DNA fragment containing *gpt* was amplified by PCR using two primers (primer 1 (forward): 5′-TACCACTTTATCCCGCGTCAGG-3′, primer 2 (reverse): 5′-ACAGGGTTTCGCTCAGGTTTGC-3′). The reaction mixture contained 5 pmol of each primer and 200 μM of each dNTP. PCR amplification was carried out using Taq DNA polymerase (Takara Bio, Shiga, Japan) with a GeneAmp PCR System 9700 (Applied Biosystems, Foster City, CA, USA). The reaction was started by incubation at 96 °C for 180 s, followed by 29 cycles of 30 s at 94 °C, 30 s at 58 °C, 60 s at 72 °C and an additional 180 s incubation at 72 °C after the final cycle.

PCR products were purified using Exo-SAP It (GE Healthcare Bio-Sciences Corp., Piscataway, NJ, USA). DNA sequencing of *gpt* was performed using Big Dye Terminator v3.1 (Applied Biosystems) on an ABI PRISM 3100 Genetic Analyzer (Applied Biosystems) with sequencing primer (5′-ATCTCTATAATCTCGCGCAACC-3′) according to the manufacturer's instructions. Oligonucleotide primers were obtained from Hokkaido System Science (Sapporo, Japan).

2.8. Statistical analysis

Mutant frequency is presented as mean ± S.D. Statistical significance was evaluated with the Student's *t*-test and Fisher's exact test using Graphpad Prism software (Graphpad Software Inc., San Diego, CA, USA). $P < 0.05$ was considered statistically significant.

3. Results

3.1. Thymus weight after treatment with ENU and X-rays

First, we measured body and thymus weight after combined exposure to X-rays and ENU (Table 1). The thymus weight of mice exposed to 0.2 or 1.0 Gy X-rays, ENU alone, or 0.2 Gy X-rays followed by ENU did not differ from that of non-irradiated controls. Thymus from mice exposed to 1.0 Gy X-rays followed by ENU weighed slightly greater than control thymus (68 ± 22 mg vs. 43 ± 9 mg; $P < 0.05$), suggestive of an onset of leukemogenesis. The body weight of all treated mice, except the 0.2 Gy followed by ENU mice, did not differ significantly from control.

3.2. Thymus gpt mutant frequency analysis

The *gpt* reporter transgene was used to analyze the occurrence of mutations in the thymus. The frequency of *gpt* mutants in each control and treated thymus is shown in Table 1 and Fig. 2. It is evident that ENU increased mutant frequency by 10-fold relative to untreated controls. Surprisingly, the mutant frequency in mice exposed to 0.2 or 1.0 Gy X-rays alone was significantly reduced compared to the control ($P < 0.05$). The mutant frequency in mice exposed to 0.2 Gy X-rays in combination with ENU was also, unexpectedly, reduced compared to ENU treatment alone, almost to the level of the untreated controls. In contrast, exposure



Fig. 2. Mutant frequency analysis of *gpt*⁻ recovered from thymus DNA from control, irradiated (0.2 or 1.0 Gy), ENU-treated, and irradiated/ENU-treated mice. The inset shows an expanded scale for mutant frequency for the first three conditions. $^{*}P < 0.05$, significantly different from control. $^{**}P < 0.05$, significantly different from ENU. Bars represent mean ± S.D.

to 1.0 Gy X-rays in combination with ENU increased the mutant frequency by 3-fold compared to ENU treatment alone. In mouse #30 of ENU group, mutant frequency was not different from that in control group (0.91×10^{-5} vs. 1.20×10^{-5}), but the weight of thymus was significantly increased compared with control (Table 1). These results suggested that the thymocyte with no *gpt* mutation expanded in this mouse.

3.3. Characteristics of the gpt mutants

The class- and site-distribution of mutations are shown in Tables 2 and 3, respectively.

In control group, G:C to A:T mutation was predominantly detected, especially at both non-CpG and CpG sites (0.24×10^{-5} and 0.30×10^{-5}, respectively). In 0.2 and 1.0 Gy groups, however, G:C to A:T mutation at CpG was reduced by 6-fold compared to control, respectively (0.2 Gy, 0.05×10^{-5}; 1.0 Gy, 0.05×10^{-5}). In ENU group, G:C to A:T mutation was generated at non-CpG sites (8.26×10^{-5}) especially at positions 86 and 409. These sites might be hot spot for mutation by ENU, because four out of five mice commonly had these mutations. In addition, mutants with G:C to T:A and A:T to T:A in ENU group were also increased at the rate of 1.47×10^{-5} and 2.36×10^{-5}, respectively.

In 0.2 Gy followed by ENU group, however, the mutant frequency of G:C to A:T and A:T to T:A was significantly reduced compared to the ENU-treated group ($P < 0.001$). Particularly, mutants with G:C to A:T transitions decreased by 37-fold (ENU, 8.26×10^{-5}; 0.2 Gy + ENU, 0.24×10^{-5}).

In three mice of 1.0 Gy followed by ENU group, more than 1000 mutants were detected per thymus (#26, 27 and 29); 201, 168 and 135 mutants were analyzed for each mouse, respectively (Table 3). The class- and site-distribution of mutations differed between mice and jackpot mutation was shown. In mouse #26, 143 of 201 mutations were G:C to A:T transitions at position 87. Almost all of the mutations (164 of 168) detected in mouse #27 were A:T to C:G transversions at position 106 (Table 3). Ninety-eight of 135 mutations in mouse #29 were A:T to G:C transition

Please cite this article in press as: K. Yamauchi, et al., Differential effects of low- and high-dose X-rays on N-ethyl-N-nitrosourea-induced mutagenesis in thymocytes of B6C3F1 *gpt*-delta mice, Mutat. Res., Fundam. Mol. Mech. Mutagen. (2008), doi:10.1016/j.mrfmmm.2007.12.007

Table 1
Mutant and mutation frequency in thymus DNA from control, irradiated, ENU-treated, and combined treated mice

Treatment	Mouse ID	Body weight (g)	Average ± S.D. (mg)	Thymus weight (mg)	Average ± S.D. (mg)	Number of Cm colonies ($\times 10^5$)	Number of mutants	Mutant frequency ($\times 10^{-5}$)	Average ± S.D. ($\times 10^{-5}$)	Number of mutants sequenced	Number of independent mutants	Independent mutants (%)	Mutation frequency ($\times 10^{-5}$)	Average ± S.D. ($\times 10^{-5}$)
Control	1	25.7		45		18.3	32	1.75		28	22	79	1.38	
	2	25.8		39		12.7	16	1.26		14	13	93	1.17	
	3	24.6	26.5 ± 1.7	57	43 ± 9	16.2	21	1.30	1.2 ± 0.48	15	10	67	0.86	1.00 ± 0.43
	4	28.6		38		13.4	17	1.27		9	9	100	1.27	
	5	28.1		36		35.8	15	0.42		14	10	71	0.30	
	6	27.0		48		5.3	6	1.14		4	4	100	1.14	
	7	28.4		49		31.5	1	0.03		0	0	N.D.	N.D.	
0.2 Gy	8	24.6	26.3 ± 1.6	39	46 ± 6	28.3	4	0.14	0.39 ± 0.46*	1	1	100	0.14	0.59 ± 0.51[a]
	9	27.1		53		6.9	1	0.14		0	0	N.D.	N.D.	
	10	24.7		56		6.0	3	0.50		3	3	100	0.50	
	11	25.2		45		18.3	15	0.82		12	10	83	0.68	
	12	25.6		48		23.4	8	0.34		8	7	88	0.30	
1.0 Gy	13	24.6	25.0 ± 0.5	45	46 ± 1	47.8	12	0.25	0.53 ± 0.29*	9	9	100	0.25	0.49 ± 0.27
	14	24.5		45		15.0	13	0.87		10	10	100	0.87	
	15	25.5		47		8.5	3	0.35		2	2	100	0.35	
	16	24.5		35		17.7	110	6.21		110	15	14	0.85	
	17	26.7		43		2.3	66	28.21		58	12	21	5.84	
ENU	18	24.6	25.1 ± 1.0	36	41 ± 5	20.6	281	13.62	12.56 ± 9.67*	274	25	9	1.24	2.01 ± 2.15
	19	25.2		45		53.4	616	11.54		110	9	8	0.94	
	20	24.4		45		13.3	43	3.23		38	14	37	1.19	
	21	24.0		39		8.0	6	0.75		6	6	100	0.75	
	22	24.9		41		28.8	31	1.08		31	19	61	0.66	
0.2 Gy + ENU	23	24.6	24.4 ± 0.4*	35	40 ± 4	7.4	11	1.48	1.74 ± 1.76	10	9	90	1.34	1.12 ± 0.79
	24	24.8		47		5.0	24	4.82		22	11	50	2.41	
	25	24.0		38		31.3	18	0.57		17	13	76	0.44	
	26	24.4		64		18.5	1028	55.72		201	7	3	1.94	
	27	25.4		43		20.9	1001	47.94		168	5	3	1.43	
1.0 Gy + ENU	28	24.6	24.8 ± 0.9	100	68 ± 22*	5.7	75	13.09	34.74 ± 25.90*	59	8	14	1.77	1.61 ± 0.50
	29	25.9		54		27.5	1539	56.07		135	5	4	2.08	
	30	23.8		77		15.4	14	0.91		11	10	91	0.83	

N.D.: not determined.
[a] $n = 3$.
* $P < 0.05$, statistically significant difference vs. control.

Table 2
Classification and mutant frequency (M.F.) and mutation frequency (m.f.) of *gpt* mutations recovered from thymus DNA from control, irradiated, ENU-treated, and combined treated mice

	Control			0.2 Gy			1.0 Gy			ENU			0.2 Gy + ENU			1.0 Gy + ENU		
	No.	M.F. ($\times 10^{-5}$)	No.	m.f. ($\times 10^{-5}$)	No.	M.F. ($\times 10^{-5}$)	No.	m.f. ($\times 10^{-5}$)[a]	No.	M.F. ($\times 10^{-5}$)	No.	m.f. ($\times 10^{-5}$)	No.	M.F. ($\times 10^{-5}$)	No.	m.f. ($\times 10^{-5}$)	No.	M.F. ($\times 10^{-5}$)	No.	m.f. ($\times 10^{-5}$)
G:C to A:T (at non-CpG)	16	0.24	15	0.23	5	0.24	5	0.37	8	0.10	7	0.09	388	8.26	20	0.54	12	0.24	11	0.21	149	9.02	6	0.28
G:C to A:T (at CpG)[b]	20	0.30	11	0.17	1	0.05	1	0.07	4	0.05	3	0.04	1	0.02	1	0.03	7	0.14	5	0.10	5	0.30	4	0.18
G:C to T:A	16	0.24	15	0.23	0	<0.05	0	<0.07	12	0.16	12	0.15	69	1.47	15	0.40	15	0.30	10	0.19	20	1.21	4	0.18
G:C to C:G	3	0.05	3	0.05	0	<0.05	0	<0.07	1	0.01	1	0.01	2	0.04	2	0.05	0	<0.02	0	<0.02	1	0.06	1	0.05
Total G:C[c]	55	0.83	44	0.69	6	0.29	6	0.44	25	0.32	23	0.30	460	9.79	38	1.02	34	0.69	26	0.50	175	10.59	15	0.69
A:T to G:C	11	0.17	7	0.11	0	<0.05	0	<0.07	7	0.09	6	0.08	4	0.09	4	0.11	17	0.34	8	0.15	103	6.23	6	0.28
A:T to T:A	0	<0.02	0	<0.02	1	0.05	1	0.07	1	0.01	1	0.01	111	2.36	24	0.64	31	0.63	20	0.39	129	7.81	10	0.46
A:T to C:G	1	0.02	1	0.02	1	0.05	1	0.07	1	0.01	1	0.01	13	0.28	7	0.19	2	0.04	2	0.04	164	9.93	1	0.05
Total A:T[c]	12	0.18	8	0.13	2	0.10	2	0.15	9	0.12	8	0.10	128	2.72	35	0.94	50	1.01	30	0.58	396	23.97	17	0.78
1 bp deletion	6	0.09	6	0.09	0	<0.05	0	<0.07	6	0.08	6	0.08	2	0.04	2	0.05	1	0.02	1	0.02	2	0.12	2	0.09
1 bp insertion	2	0.03	2	0.03	0	<0.05	0	<0.07	1	0.01	1	0.01	0	<0.02	0	<0.02	1	0.02	1	0.02	1	0.06	1	0.05
>2 bp frameshifts	5	0.08	4	0.06	0	<0.05	0	<0.07	0	<0.01	0	<0.01	0	<0.02	0	<0.02	0	<0.02	0	<0.02	0	<0.06	0	<0.05
Total frameshifts	13	0.20	12	0.19	0	<0.05	0	<0.07	7	0.09	7	0.09	2	0.04	2	0.05	2	0.04	2	0.04	3	0.18	3	0.14
Total	80	1.20	64	1.00	8	0.39	8	0.59	41	0.53	38	0.49	590	12.56	75	2.01	86	1.74	58	1.12	574	34.74	35	1.61

No.: number of mutation(s). M.F.: specific mutant frequency was calculated by multiplying the mutant frequency by the ratio of the number of mutations in each class among the total number of *gpt* mutants. m.f.: specific mutation frequency was calculated by multiplying the mutation frequency by the ratio of independent mutation in each class to the total number of independent *gpt* mutant.

[a] $n = 3$.

[b] Number of occurrences of the G:C to A:T mutation at the 5′-CpG-3′ site.

[c] Total number of mutations occurring at G:C or A:T base pairs.

at position 419. These results indicate that the increased frequency of mutation in this group was caused by clonal expansion of cells possessing a unique mutation. None of the mutation sites were identical to those observed as hot spots in mice treated with ENU alone.

3.4. Mutation frequency

Unlike mutant frequency, difference in overall mutation frequency after ENU was calculated to be small among groups. However, A:T to T:A mutation frequency in ENU group, either combined or not combined with 1.0 Gy X-rays, was increased compared with control or X-ray irradiation groups (Table 2), while mutation at G:C sites remained unchanged statistically. The total mutation frequency by ENU group reduced from 2.01×10^{-5} to 1.12×10^{-5} when combined with 0.2 Gy, although statistically not significant. In contrast, repeated 1.0 Gy did not alter the overall frequency of ENU-induced mutation (1.61×10^{-5}).

3.5. Clonality of gpt mutations

The mutant frequency was significantly larger than mutation frequency in the groups treated with ENU alone, and with 1.0 Gy combined with ENU (Table 1). This means that mutation occurrence in ENU and 1.0 Gy combined with ENU groups were mainly caused by clonal expansion. We established the approximate level of clonality for each group. Clonality was less than 20% in the control group, which was the same as that observed in *lacI* transgenic mice [19]. Clonalities in 0.2 Gy X-ray and 1.0 Gy X-ray groups were also similar to that in the control group. It increased dramatically to over 80% in the ENU-treated group (Fig. 3). When 0.2 Gy X-ray exposure was combined with ENU, clonality was drastically reduced compared with ENU alone (24.6% vs. 82.2%, $P < 0.001$). In contrast, 1.0 Gy X-rays, except mouse #30, facilitated clonal expansion of mutated cells, as shown by the high percentage of subpopulations with specific mutations and the shift from an oligoclonal to monoclonal population (Table 3).

4. Discussion

In this study we investigated the combined effect of ENU and X-rays on the occurrence of mutations in the reporter transgene *gpt* in mouse thymus DNA. Repeated irradiation with 0.2 Gy X-rays not only reduced background mutation levels, but also suppressed ENU-induced mutations and clonal expansion. In contrast, 1.0 Gy irradiation in combination with ENU accelerated clonal expansion of mutated cells.

Reduction of the background mutation frequency by repeated dosing with 0.2 Gy X-rays or 1.0 Gy X-rays was unexpected. A decrease in G:C site mutations, including G:C to A:T at the CpG site, primarily accounted for this effect. The *gpt* in *gpt*-delta transgenic mice may be methylated at the CpG site [21]. Mammalian cell, in general, is heavily methylated at C-5 of cytosine residues at CpG dinucleotides. When 5-methylcytosine was deaminated, it converts to thymine, which results in G:C

Please cite this article in press as: K. Yamauchi et al., Differential effects of low- and high-dose X-rays on *N*-ethyl-*N*-nitrosourea-induced mutagenesis in thymocytes of B6C3F1 *gpt*-delta mice, Mutat. Res.: Fundam. Mol. Mech. Mutagen. (2008), doi:10.1016/j.mrfmmm.2007.12.001

Table 3
Mutational spectrum of *gpt* gene mutations recovered from thymus DNA from non-, X-ray-, ENU- and combined treated mice

Base positions[a]	CpG site	Control		0.2 Gy		1.0 Gy		ENU		0.2 Gy + ENU		1.0 Gy + ENU	
		No. of mutant	No. of independent mutation (mouse ID)	No. of mutant	No. of independent mutation (mouse ID)[b]	No. of mutant	No. of independent mutation (mouse ID)	No. of mutant	No. of independent mutation (mouse ID)	No. of mutant	No. of independent mutation (mouse ID)	No. of mutant	No. of independent mutation (mouse ID)
G:C to A:T													
3		2	2 (1, 4)										
7	CpG					1	1 (14)						
37		1	1 (5)										
58	CpG												
64	CpG	12	4 (1,2,3, 5)	1	1 (6)	2	1 (11)			3	2 (21,25)	1	1 (28)
86								194	4 (16,17,18,19)				
87								1	1 (18)			143	1 (26)
92				2	2 (6,8)					1	1 (22)	1	1 (26)
107		2	2 (1, 2)										
109	CpG	2	1 (5)										
110	CpG	1	1 (3)							3	2 (21,22)	2	1 (26)
113				1	1 (10)			2	2 (19,20)				
115	CpG	3	3 (2,3,4)			1	1 (12)	1	1 (17)	1	1 (22)	1	1 (27)
116								19	2 (16,18)				
128		1	1 (1)					83	2 (19,20)				
176						1	1 (11)	2	2 (17,19)			1	1 (30)
189								1	1 (19)				
262						1	1 (12)					1	1 (28)
274		2	2 (1,2)	1	1 (10)			1	1 (19)	1	1 (21)	2	1 (30)
280	CpG	1	1 (2)										
281		1	1 (1)			1	1 (15)					1	1 (30)
287								1	1 (16)				
301	CpG											1	1 (28)
391										1	1 (22)		
401				1	1 (6)	1	1 (13)			1	1 (22)		
402										2	2 (21,23)	1	1 (26)
406		3	2 (1,2)							1	1 (22)		
409								84	4 (16,17,18,19)			1	1 (26)
413	CpG	1	1 (2)			1	1 (13)						
417		1	1 (2)										
418		3	3 (1,2,5)			3	2 (11,12)						
										5	4 (22,23,24,25)		
Total at non-CpG		16	15	5	5	8	7	388[c]	20	12	11	149[c]	6
Total at CpG		20	11	1	1	4	3	1[c]	1	7	5	5[c]	4
G:C to T:A													
3												1	1 (30)
7	CpG					1	1 (11)	32	2 (16,18)				
15								1	1 (18)				
19	CpG												
26						1	1 (12)			1	1 (24)		
37						1	1 (13)						

Please cite this article in press as: K. Yamauchi, et al., Differential effects of low- and high-dose X-rays on *N*-ethyl-*N*-nitrosourea-induced mutagenesis in thymocytes of B6C3F1 *gpt* delta mice, Mutat. Res.: Fundam. Mol. Mech. Mutagen. (2008), doi:10.1016/j.mrfmmm.2007.12.001

79										1	1(27)
109	CpG	1	1 (4)								
110	CpG	1	1 (4)								
113						1	1 (16)				
115	CpG	1	1 (1)	1	1 (13)			1	1 (24)		
116		1	1 (3)	1	1 (15)	1	1 (16)				
143	CpG	1	1 (3)					1	1 (22)		
176				1	1 (14)						
185		1	1 (2)								
189								1	1 (23)		
190	CpG							1	1 (22)		
208	CpG					1	1 (18)	9	4 (22,23,24,25)	1	1(28)
232		1	1 (1)								
244	CpG	1	1 (5)	1	1 (13)	8	2 (18,19)				
265						3	2 (16,18)				
304		2	2 (1,2)								
401		1	1 (5)			19	3 (16,17,18)				
402		3	2 (1,5)	3	3 (11,13,14)						
406		1	1 (1)	1	1 (14)	1	1 (17)				
409		1	1 (1)			2	1 (17)	1	1 (24)	17	1(29)
418				1	1 (13)						
Total		16	15	12	12	69*	15	15	10	20*	4
G:C to C:G											
7	CpG					1	1 (17)			1	1(30)
115	CpG	1	1 (1)								
125	CpG					1	1 (18)				
289		1	1 (1)								
402				1	1 (15)						
436	CpG	1	1 (4)								
Total		3	3	1	1	2	2			1	1
A:T to G:C											
2		2	2 (4,5)							1	1(30)
8								1	1 (25)	1	1(29)
25		4	3 (1,2,4)								
56				1	1 (14)						
119								9	2 (22,25)		
149								1	1 (24)		
175				1	1 (11)						
181						1	1 (17)				
187						1	1 (17)			1	1(30)
188								1	1 (22)		
191								1	1 (21)	1	1(30)
269		2	1 (5)	1	1 (14)			1	1 (25)		
275										1	1(27)
277								3	1 (22)		
343				1	1 (14)						
419		3	1 (1)	3	2 (11,14)	1	1 (17)			98	1(29)
457						1	1 (18)				
Total		11	7	7	6	4	4	17	8	103*	6
A:T to T:A											
2						2	2 (18,19)	1	1 (25)		
12				1	1 (13)						
35								1	1 (25)	18	1(29)
52						5	2 (16,18)			1	1(27)
56						1	1 (18)				
81								1	1 (22)		
88						14	1 (19)	8	2 (23,24)	43	2(26, 28)
95								1	1 (25)		
134						16	4 (16,17,18,19)				

Table 3 (*Continued*)

Base positions[a]	CpG site	Control		0.2 Gy		1.0 Gy		ENU		0.2 Gy + ENU		1.0 Gy + ENU	
		No. of mutant	No. of independent mutation (mouse ID)	No. of mutant	No. of independent mutation (mouse ID)[b]	No. of mutant	No. of independent mutation (mouse ID)	No. of mutant	No. of independent mutation (mouse ID)	No. of mutant	No. of independent mutation (mouse ID)	No. of mutant	No. of independent mutation (mouse ID)
164				1	1(6)			3	3 (16,18,19)	2	2 (24,25)		
173								1	1 (18)				
177										1	1 (23)		
214										1	1 (24)		
223												1	1(30)
254												1	1(28)
257								2	1 (16)			1	1(28)
260										1	1 (25)		
263								8	2 (18,19)	7	3 (22,23,24)	63	2(26, 28)
312								1	1 (19)	2	1 (22)		
329								1	1 (18)			1	1(30)
345								56	4 (16,17,18,19)				
375										1	1 (22)		
400										2	2 (23,24)		
407										1	1 (23)		
420								1	1 (19)	1	1 (22)		
Total				1	1	1	1	111*	24*	31*	20*	129*	10*
A:T to C:G													
1								8	4 (16,17,18,19)				
9								1	1 (19)				
65				1	1(10)								
106								2	1 (19)			164	1(27)
218		1 (1)	1										
312										1	1 (25)		
331										1	1 (25)		
345						1	1 (14)	2	1 (18)				
Total		1	1	1	1	1	1	13	7	2	2	164*	1

No. of mutants: total number of mutations detected, include clonal mutations. Total number was shown the total number of mutations. No. of independent mutations: total number was shown the total number of independent mutations. The data were corrected for any clonal expansions by counting only one mutation when multiple identical mutations were recovered form an individual mouse. ID of mice with a mutation was shown in parentheses on the right-hand side of the total number of independent mutations.

[a] Position in the *gpt* coding sequence when A of start codon is labeled as 1.

[b] $n = 3$.

* $P < 0.05$ vs. control.



Fig. 3. Mutation clonality was enhanced by ENU as well as by 1.0 Gy X-rays in combination with ENU, but was suppressed by repeated irradiation with 0.2 Gy X-rays before ENU treatment. $^{*}P < 0.05$, significantly different from control. $^{**}P < 0.05$, significantly different from ENU. Bars represent means.

to A:T mutation after DNA replication if G:T mismatch is not repaired [22]. Repeated irradiation with 0.5 Gy X-rays leads to a decrease in DNA methylation via loss of histone H4-Lys20 trimethylation in thymus tissue [23], which could account for the reduced G:C to A:T mutation occurrence at CpG sites. Low-dose radiation (within 0.2 Gy) reduces thymic DNA fragmentation and apoptosis relative to non-irradiated background levels [24], suggesting that activation of DNA repair mechanisms may also contribute to the reduced frequency of mutations.

We show here that repeated 0.2 Gy irradiation also dramatically reduces ENU-induced mutations and the number of hot spot sites, primarily by decreasing the number of G:C to A:T transitions and G:C to T:A and A:T to T:A transversions. ENU produces ethylated base damage such as O^6-ethylguanine, O^4-ethylthymine and O^2-ethylthymine, which induces G:C to A:T transition, A:T to G:C transition and A:T to T:A transversion, respectively [4–8]. Base damage can be removed by multiple DNA repair systems. O^6-Methylguanine-DNA methyltransferase (*Mgmt*) recognizes and directly binds O^6-ethylguanine and removes the ethyl residue, thereby preventing G:C to A:T transition [25–28]. It is shown that transient expression of *Mgmt* is stimulated by X-irradiation both *in vitro* and *in vivo* within 3–48 h [29–31]. Importantly, the inductive effect of X-irradiation on O^6-alkylguanine-DNA alkyltransferase activity corresponds with a reduced incidence of rat CNS tumors after X-irradiation combination with ENU [10]. We have also examined if the expression of *Mgmt* mRNA increased after repeated X-irradiation of 0.2 Gy followed by ENU treatment. It turned out that the induction of *Mgmt* was negligible in irradiated thymus: fold increase was just 1.1 after the last irradiation. Subsequent ENU treatment increased *Mgmt* expression as a function of time. The 2-fold induction of *Mgmt* in thymus with 0.2 Gy followed by ENU, however, was smaller than 3.9-fold induction in thymus with ENU alone. Therefore, decrease in mutation frequency by 0.2 Gy could not be explained by expression level of *Mgmt*. Mechanism(s) other than *Mgmt* induction might be involved. Nucleotide excision repair can also repair alkylating base damage [32–34]. Chinese hamster ovary cells lacking *XPD/ERCC2* are highly susceptible to ENU-induced *Hprt* mutations [32]. DNA microarray studies indicate that *XPC* is up-regulated in human blood lymphocytes after 0.2 Gy X-ray exposure [35]. Taken together, it is required to determine activation or inactivation of other DNA repair pathways that reduce or enhance the overall rate of ENU-induced mutations.

We noticed that ENU mutations were predominantly induced at A:T site. It is reported that O^6-ethylguanine was repaired fast by *Mgmt* and nucleotide excision repair, while O^4-ethylthymine and O^2-ethylthymine were persistent lesions and the repair of these lesions occurred only at a very slow rate [25,32,36]. *In vivo* mutagenicity assays in mouse T lymphocytes have shown that predominant mutations induced by ENU are A:T to T:A [37].

Cells with hot spot point mutations expanded oligoclonally after ENU treatment. Clonal thymic lymphomas selected from oligoclonal preleukemic cells have been reported in virus-induced or radiation-induced T-cell lymphomagenesis [38,39]. Interestingly, the treatment with 0.2 Gy X-rays followed by ENU reduced oligoclonality, whereas 1.0 Gy X-rays accelerated ENU-induced clonal expansion. It is reported that high-dose whole body irradiation at 1.0 Gy induced p53 dependent transcription of *Noxa*, *Killer/DR5*, *Fas*, *Pidd* and *Perp* genes in thymus, whereas irradiation at 0.2 Gy did not induce these gene expressions [40]. Low-dose irradiation likely again activates multiple repair pathways and cell cycle control. In contrast, high-dose radiation may select specific clones with a growth advantage.

Point mutations of K-*ras*, *p53* and *Ikaros* occur frequently in ENU-induced T-cell lymphomas [41,42]. These mutations may enhance responsiveness of cells to growth factor induction of proliferation or resistance to apoptosis, thereby improving survival and increasing clonal expansion. When myeloma cells are cultured on normal bone marrow stromal cells, or in the presence of IL-6, activation of the K-*ras* oncogene provides a growth advantage over cells lacking activated K-*ras* [43]. The progression from low grade to high-grade brain tumors is associated with clonal expansion of cells that have acquired a *p53* mutation that endows the cells with a selective growth advantage [44]. T-cells with reduced or dominant-negative Ikaros activity, which may result from either a lack of or a point mutation in the zinc finger responsible for DNA binding, exhibit a greater proliferative response to IL-2 [45,46]. Irradiation of thymic epithelial cells enhances IL-7 production, and thymocytes at preleukemic stage proliferate more vigorously in response to IL-7 [47,48]. Taken together, these results suggest that high-dose radiation provides a thymic microenvironment ripe for the occurrence of prelymphoma cells, which harbor growth-advantageous mutations following ENU treatment.

In conclusion, low-dose X-rays (0.2 Gy) reduce not only the frequency of spontaneously occurring but also ENU-induced

Please cite this article in press as: K. Yamauchi, et al., Differential effects of low and high dose X-rays on N-ethyl-N-nitrosourea-induced mutagenesis in thymocytes of B6C3F1 *gpt*-delta mice, Mutat. Res. Fundam. Mol. Mech. Mutagen. (2008), doi:10.1016/j.mrfmmm.2007.12.001

mutations, suggestive of an adaptive response. Low-dose X-rays also reduce the clonal expansion of cells following ENU treatment, whereas 1.0 Gy X-rays accelerate cell expansion. Thus, low- and high-dose radiations play two different roles in lymphomagenesis when combined with ENU exposure.

Acknowledgements

We thank Dr. T. Shiomi, The Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, and Dr. M. Ohta, Health Risk Assessment Section, National Institute for Environmental Studies, for technical advices. We also thank Ms. S. Amasaki, Ms. U. Enzaka, Ms. M. Okabe, Mr. J Nagai, Ms. S. Hirano and Ms. Y. Miyayama and the staff in Animal Facility of our institute for their assistance in laboratory analysis and mouse husbandry.

This work was supported in part by a grant from the Long-range Research Initiative (LRI) of the Japan Chemical Industry Association (JCIA), a grant from the 'Ground-based Research Announcement for Space Utilization' promoted by the Japan Space Forum, a grant from the Ministry of Health, Labour and Welfare, Japan, and a Grant-in-Aid from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.

References

[1] E.C. Friedberg, G.C. Walker, W. Siede, R.D. Wood, R.A. Schultz, T. Ellenberger, DNA Repair And Mutagenesis, second edition, ASM Press, Washington DC, 2005.

[2] T. Shibuya, K. Morimoto, A review of the genotoxicity of 1-ethyl-1-nitrosourea, Mutat. Res. 297 (1993) 3–38.

[3] D.T. Beranek, Distribution of methyl and ethyl adducts following alkylation with monofunctional alkylating agents, Mutat. Res. 231 (1990) 11–30.

[4] J.C. Klein, M.J. Bleeker, J.T. Lutgerink, W.J. van Dijk, H.F. Brugghe, H. van den Elst, G.A. van der Marel, J.H. van Boom, J.G. Westra, A.J. Berns, et al., Use of shuttle vectors to study the molecular processing of defined carcinogen-induced DNA damage: mutagenicity of single O4-ethylthymine adducts in HeLa cells, Nucleic Acids Res. 18 (1990) 4131–4137.

[5] K.S. Ellison, E. Dogliotti, T.D. Connors, A.K. Basu, J.M. Essigmann, Site-specific mutagenesis by O6-alkylguanines located in the chromosomes of mammalian cells: influence of the mammalian O6-alkylguanine-DNA alkyltransferase, Proc. Natl. Acad. Sci. U.S.A. 86 (1989) 8620–8624.

[6] O.S. Bhanot, P.C. Grevatt, J.M. Donahue, C.N. Gabrielides, J.J. Solomon, In vitro DNA replication implicates O2-ethyldeoxythymidine in transversion mutagenesis by ethylating agents, Nucleic Acids Res. 20 (1992) 587–594.

[7] J.G. Jansen, G.R. Mohn, H. Vrieling, C.M. van Teijlingen, P.H. Lohman, A.A. van Zeeland, Molecular analysis of hprt gene mutations in skin fibroblasts of rats exposed in vivo to *N*-methyl-*N*-nitrosourea or *N*-ethyl-*N*-nitrosourea, Cancer Res. 54 (1994) 2478–2485.

[8] B. Singer, M.K. Dosanjh, Site-directed mutagenesis for quantitation of base–base interactions at defined sites, Mutat. Res. 233 (1990) 45–51.

[9] T. Seyama, T. Kajitani, A. Inoh, K. Yanagihara, K. Kamiya, K. Yokoro, Synergistic effect of radiation and *N*-nitrosoethylurea in the induction of lymphoma in mice: cellular kinetics and carcinogenesis, Jpn. J. Cancer Res. 76 (1985) 20–27.

[10] I. Stammberger, W. Schmahl, L. Nice, The effects of X-irradiation, *N*-ethyl-*N*-nitrosourea or combined treatment on O6-alkylguanine-DNA alkyltransferase activity in fetal rat brain and liver and the induction of CNS tumours, Carcinogenesis 11 (1990) 219–222.

[11] D.A. Kantorowitz, H.J. Thompson, P. Furmanski, Effect of high-dose, fractionated local irradiation on MNU-induced carcinogenesis in the rat mammary gland, Carcinogenesis 16 (1995) 649–653.

[12] Y. Morishita, T. Tanaka, H. Mori, S. Sasaki, Effects of X-irradiation on *N*-methyl-*N*-nitrosourea-induced multi-organ carcinogenesis in rats, Jpn. J. Cancer Res. 84 (1993) 26–33.

[13] H.J. Seidel, Effects of radiation and other influences on chemical lymphomagenesis, Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. 51 (1987) 1041–1048.

[14] T. Nohmi, M. Katoh, H. Suzuki, M. Matsui, M. Yamada, M. Watanabe, M. Suzuki, N. Horiya, O. Ueda, T. Shibuya, H. Ikeda, T. Sofuni, A new transgenic mouse mutagenesis test system using Spi- and 6-thioguanine selections, Environ. Mol. Mutagen. 28 (1996) 465–470.

[15] H.S. Kaplan, M.B. Brown, A quantitative dose–response study of lymphoid-tumor development in irradiated C 57 black mice, J. Natl. Cancer Inst. 13 (1952) 185–208.

[16] T. Nohmi, T. Suzuki, K. Masumura, Recent advances in the protocols of transgenic mouse mutation assays, Mutat. Res. 455 (2000) 191–215.

[17] S.E. Andrew, A.H. Reitmair, J. Fox, L. Hsiao, A. Francis, M. McKinnon, T.W. Mak, F.R. Jirik, Base transitions dominate the mutational spectrum of a transgenic reporter gene in MSH2 deficient mice, Oncogene 15 (1997) 123–129.

[18] J.C. Mirsalis, J.A. Shimon, A. Johnson, D. Fairchild, N. Kanazawa, T. Nguyen, J. de Boer, B. Glickman, R.A. Winegar, Evaluation of mutant frequencies of chemically induced tumors and normal tissues in lambda/cII transgenic mice, Environ. Mol. Mutagen. 45 (2005) 17–35.

[19] S. Zhang, B.W. Glickman, J.G. de Boer, Spontaneous mutation of the lacI transgene in rodents: absence of species, strain, and insertion-site influence, Environ. Mol. Mutagen. 37 (2001) 141–146.

[20] S. Zhang, R. Lloyd, G. Bowden, B.W. Glickman, J.G. de Boer, Thymic lymphomas arising in Msh2 deficient mice display a large increase in mutation frequency and an altered mutational spectrum, Mutat. Res. 500 (2002) 67–74.

[21] K. Masumura, M. Matsui, M. Katoh, N. Horiya, O. Ueda, H. Tanabe, M. Yamada, H. Suzuki, T. Sofuni, T. Nohmi, Spectra of *gpt* mutations in ethylnitrosourea-treated and untreated transgenic mice, Environ. Mol. Mutagen. 34 (1999) 1–8.

[22] B.K. Duncan, J.H. Miller, Mutagenic deamination of cytosine residues in DNA, Nature 287 (1980) 560–561.

[23] I. Pogribny, I. Koturbash, V. Tryndyak, D. Hudson, S.M. Stevenson, O. Sedelnikova, W. Bonner, O. Kovalchuk, Fractionated low-dose radiation exposure leads to accumulation of DNA damage and profound alterations in DNA and histone methylation in the murine thymus, Mol. Cancer Res. 3 (2005) 553–561.

[24] S.Z. Liu, Y.C. Zhang, Y. Mu, X. Su, J.X. Liu, Thymocyte apoptosis in response to low-dose radiation, Mutat. Res. 358 (1996) 185–191.

[25] S.M. Bronstein, T.R. Skopek, J.A. Swenberg, Efficient repair of O6-ethylguanine, but not O4-ethylthymine or O2-ethylthymine, is dependent upon O6-alkylguanine-DNA alkyltransferase and nucleotide excision repair activities in human cells, Cancer Res. 52 (1992) 2008–2011.

[26] M. Bignami, E. Dogliotti, G. Aquilina, A. Zijno, C.P. Wild, R. Montesano, O6-methyltransferase-deficient and -proficient CHO cells differ in their responses to ethyl- and methyl-nitrosourea-induced DNA alkylation, Carcinogenesis 10 (1989) 1329–1332.

[27] F. Drablos, E. Feyzi, P.A. Aas, C.B. Vaagbo, B. Kavli, M.S. Bratlie, J. Pena-Diaz, M. Otterlei, G. Slupphaug, H.E. Krokan, Alkylation damage in DNA and RNA-repair mechanisms and medical significance, DNA Repair (Amst.) 3 (2004) 1389–1407.

[28] A.E. Pegg, Repair of O(6)-alkylguanine by alkyltransferases, Mutat. Res. 462 (2000) 83–100.

[29] P. Lefebvre, F. Laval, Enhancement of O6-methylguanine-DNA-methyltransferase activity induced by various treatments in mammalian cells, Cancer Res. 46 (1986) 5701–5705.

[30] C.L. Chan, Z. Wu, A. Eastman, E. Bresnick, Irradiation-induced expression of O6-methylguanine-DNA methyltransferase in mammalian cells, Cancer Res. 52 (1992) 1804–1809.

Please cite this article in press as: K. Yamauchi, et al., Differential effects of low- and high-dose X-rays on *N*-ethyl-*N*-nitrosourea-induced mutagenesis in thymocytes of B6C3F1 *gpt* delta mice, Mutat. Res. Fundam. Mol. Mech. Mutagen. (2008), doi:10.1016/j.mrfmmm.2007.12.001

[31] R.E. Wilson, B. Hoey, G.P. Margison, Ionizing radiation induces O6-alkylguanine-DNA-alkyltransferase mRNA and activity in mouse tissues, Carcinogenesis 14 (1993) 679–683.
[32] C.W. Op het Veld, S. van Hees-Stuivenberg, A.A. van Zeeland, J.G. Jansen, Effect of nucleotide excision repair on hprt gene mutations in rodent cells exposed to DNA ethylating agents, Mutagenesis 12 (1997) 417–424.
[33] J. Engelbergs, J. Thomale, A. Galhoff, M.F. Rajewsky, Fast repair of O6-ethylguanine, but not O6-methylguanine, in transcribed genes prevents mutation of H-ras in rat mammary tumorigenesis induced by ethylnitrosourea in place of methylnitrosourea, Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 1635–1640.
[34] A. Sitaram, G. Plitas, W. Wang, D.A. Scicchitano, Functional nucleotide excision repair is required for the preferential removal of *N*-ethylpurines from the transcribed strand of the dihydrofolate reductase gene of Chinese hamster ovary cells, Mol. Cell. Biol. 17 (1997) 564–570.
[35] S.A. Amundson, K.T. Do, S. Shahab, M. Bittner, P. Meltzer, J. Trent, A.J. Fornace Jr., Identification of potential mRNA biomarkers in peripheral blood lymphocytes for human exposure to ionizing radiation, Radiat. Res. 154 (2000) 342–346.
[36] J.G. Jansen, C.M. van Teijlingen, G.R. Mohn, A.A. van Zeeland, H. Vrieling, AT base pairs are the main targets for mutations at the hprt locus of rat skin fibroblasts exposed in vitro to the monofunctional alkylating agent *N*-ethyl-*N*-nitrosourea, Mutagenesis 9 (1994) 417–421.
[37] J.P. O'Neill, DNA damage, DNA repair, cell proliferation, and DNA replication: how do gene mutations result? Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 11137–11139.
[38] Y. Ben-David, E. Yefenof, M. Kotler, Clonal analysis of radiation leukemia virus-induced leukemic and preleukemic murine cells, Cancer Res. 47 (1987) 6590–6594.
[39] T. Shimizu, M. Muto, E. Kubo, T. Sado, H. Yamagishi, Multiple preneoplastic events and clonal selection of radiation induced mouse thymic lymphomas shown by TCR gene rearrangements, Leuk. Res. 17 (1993) 959–965.
[40] S. Alvarez, P. Drane, A. Meiller, M. Bras, V. Deguin-Chambon, V. Bouvard, E. May, A comprehensive study of p53 transcriptional activity in thymus and spleen of gamma irradiated mouse: high sensitivity of genes involved in the two main apoptotic pathways, Int. J. Radiat. Biol. 82 (2006) 761–770.
[41] Y. Shimada, M. Nishimura, S. Kakinuma, T. Takeuchi, T. Ogiu, G. Suzuki, Y. Nakata, S. Sasanuma, K. Mita, T. Sado, Characteristic association between K-ras gene mutation with loss of heterozygosity in X-ray-induced thymic lymphomas of the B6C3F1 mouse, Int. J. Radiat. Biol. 77 (2001) 465–473.
[42] S. Kakinuma, M. Nishimura, A. Kubo, J.Y. Nagai, Y. Amasaki, H.J. Majima, T. Sado, Y. Shimada, Frequent retention of heterozygosity for point mutations in p53 and Ikaros in *N*-ethyl-*N*-nitrosourea-induced mouse thymic lymphomas, Mutat. Res. 572 (2005) 132–141.
[43] D. Billadeau, P. Liu, D. Jelinek, N. Shah, T.W. LeBien, B. Van Ness, Activating mutations in the N- and K-ras oncogenes differentially affect the growth properties of the IL-6-dependent myeloma cell line ANBL6, Cancer Res. 57 (1997) 2268–2275.
[44] D. Sidransky, T. Mikkelsen, K. Schwechheimer, M.L. Rosenblum, W. Cavanee, B. Vogelstein, Clonal expansion of p53 mutant cells is associated with brain tumour progression, Nature 355 (1992) 846–847.
[45] N. Avitahl, S. Winandy, C. Friedrich, B. Jones, Y. Ge, K. Georgopoulos, Ikaros sets thresholds for T cell activation and regulates chromosome propagation, Immunity 10 (1999) 333–343.
[46] P. Papathanasiou, A.C. Perkins, B.S. Cobb, R. Ferrini, R. Sridharan, G.F. Hoyne, K.A. Nelms, S.T. Smale, C.C. Goodnow, Widespread failure of hematolymphoid differentiation caused by a recessive niche-filling allele of the Ikaros transcription factor, Immunity 19 (2003) 131–144.
[47] M. Nishimura, S. Kakinuma, D. Yamamoto, Y. Kobayashi, G. Suzuki, T. Sado, Y. Shimada, Elevated interleukin-9 receptor expression and response to interleukins-9 and -7 in thymocytes during radiation-induced T-cell lymphomagenesis in B6C3F1 mice, J. Cell Physiol. 198 (2004) 82–90.
[48] J. Toki, Y. Adachi, T. Jin, T. Fan, K. Takase, Z. Lian, H. Hayashi, M.E. Gershwin, S. Ikehara, Enhancement of IL-7 following irradiation of fetal thymus, Immunobiology 207 (2003) 247–258.

Please cite this article in press as: K. Yamauchi, et al., Differential effects on low- and high-dose X-rays on *N*-ethyl-*N*-nitrosourea-induced mutagenesis in thymocytes of B6C3F1 *gpt*-delta mice, Mutat. Res. Fundam. Mol. Mech. Mutagen. (2008), doi:10.1016/j.mrfmmm.2007.12.001

Extremophiles (2007) 11:277–282
DOI 10.1007/s00792-006-0038-x

ORIGINAL PAPER

Mariarita De Felice · Barbara Medagli
Luca Esposito · Mariarosaria De Falco
Biagio Pucci · Mosè Rossi · Petr Grùz
Takehiko Nohmi · Francesca M. Pisani

Biochemical evidence of a physical interaction between *Sulfolobus solfataricus* B-family and Y-family DNA polymerases

Received: 5 July 2006 / Accepted: 1 October 2006 / Published online: 3 November 2006

Abstract The hyper-thermophilic archaeon *Sulfolobus solfataricus* possesses two functional DNA polymerases belonging to the B-family (Sso DNA pol B1) and to the Y-family (Sso DNA pol Y1). Sso DNA pol B1 recognizes the presence of uracil and hypoxanthine in the template strand and stalls synthesis 3–4 bases upstream of this lesion ("read-ahead" function). On the other hand, Sso DNA pol Y1 is able to synthesize across these and other lesions on the template strand. Herein we report evidence that Sso DNA pol B1 physically interacts with DNA pol Y1 by surface plasmon resonance measurements and immuno-precipitation experiments. The region of DNA pol B1 responsible for this interaction has been mapped in the central portion of the polypeptide chain (from the amino acid residue 482 to 617), which includes an extended protease hyper-sensitive linker between the N- and C-terminal modules (amino acid residues Asn482-Ala497) and the α-helices forming the "fingers" sub-domain (α-helices *R*, *R'* and *S*). These results have important implications for understanding the polymerase-switching mechanism on the damaged template strand during genome replication in *S. solfataricus*.

Keywords DNA replication · Genome stability · DNA polymerase · Translesion synthesis · *Archaea* · *Sulfolobus solfataricus*

Communicated by G. Antranikian.

M. De Felice · B. Medagli · L. Esposito · M. De Falco · B. Pucci · M. Rossi · F. M. Pisani (✉)
Istituto di Biochimica delle Proteine,
Consiglio Nazionale delle Ricerche, Via P. Castellino. 111,
80131 Napoli, Italy
E-mail: fm.pisani@ibp.cnr.it
Tel.: +39-081-6132292
Fax: +39-081-6132277

P. Grùz · T. Nohmi
Division of Genetics and Mutagenesis,
National Institute of Health Sciences,
1-18-1 Kamiyoga, Setagaya-ku,
Tokyo 158-8501, Japan

Abbreviations

Sso:	*Sulfolobus solfataricus* ·
DNA pol:	DNA polymerase ·
PAGE:	Polyacrylamide gel electrophoresis ·
IPTG:	Isopropyl-β-D-thiogalactopyranoside ·
PMSF:	Phenylmethylsulfonyl fluoride ·
PVDF:	Poly(vinylidene difluoride)

Introduction

Hyper-thermophilic organisms have adopted molecular mechanisms that allow them to maintain genome stability against massive DNA damage caused by exposure to high temperature (Nohmi 2006). Spontaneous deamination, depurination and oxidation of DNA take place at greatly accelerated rate at high temperatures (Lindahl and Nyberg 1974). The hydrolytic deamination of cytosine leads to the formation of uracil in DNA and G:U base pairs result in G:C to A:T transitions in a half of the progeny if not repaired before replication. In addition, deamination of adenine results in formation of adenine that can pair with cytosine, thereby inducing A:T to G:C transitions if not repaired (Lindahl 1993). However, the spontaneous mutation rate in the hyper-thermophilic archaeon *Sulfolobus acidocaldarius* is reported to be similar to that of *Escherichia coli* (Grogan et al. 2001).

Interestingly, B-family DNA polymerases from hyper-thermophilic archaea are able to sense the presence of uracil in the template strand and tightly bind to uracil containing oligonucleotides (Lasken et al. 1996; Greagg et al. 1999). DNA polymerization is stalled when uracil is encountered four bases ahead of the primer-template junction. This "read-ahead" function appears to be a peculiar feature of the archaeal B-family DNA pols because B-family DNA polymerases from other organisms (i.e., *E. coli* bacteriophage T4 or yeast and mammals) and thermophilic bacterial A-family enzymes (i.e., *Thermus aquaticus* DNA pol) are able to read through uracil